Patents by Inventor Michael John Dawson
Michael John Dawson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9234006Abstract: Provided are compounds, the use of the said compounds in treatment, for example treatment of microbial infections, particularly by Gram negative bacteria. The compounds are polymyxin-based and are represented by the formula (I): and pharmaceutically acceptable salts thereof, where X is —NHC(O)—, —C(O)—, —OC(O)—, —CH2— or —SO2—; R5 represents C0-12 alkyl(C4-6 heterocyclyl), or C2-12 alkyl or C0-12 alkyl(C3-8 cycloalkylyl). and the alkyl or cycloalkylyl bears one, two or three hydroxyl groups, or a —NR6R7 group, or one —NR6R7 group and one or two hydroxyl groups; and R1 to R4 and R6 to R8 are as defined in the description.Type: GrantFiled: November 16, 2012Date of Patent: January 12, 2016Assignees: Novacta Biosystems Limited, Cantab Anti-Infectives LimitedInventors: Mona Saadi, Esther Duperchy, Pamela Brown, Michael John Dawson, Sjoerd Nicolaas Wadman
-
Patent number: 9006392Abstract: Described are lantibiotic-based compounds, pharmaceutical compositions comprising the same and use of the compounds and said compositions, for the treatment of microbial infection, for example Clostridium difficile or Micrococcus luteus infection. The lantibiotic-based compounds have antimicrobial activity and in comparison to one or more of actagardine, actagardine B, deoxyactagardine B and deoxyactagardine have retained activity or improved activity.Type: GrantFiled: February 1, 2011Date of Patent: April 14, 2015Assignee: Novacta Biosystems LimitedInventors: Michael John Dawson, Antony Nicholas Appleyard, Jesus Cortes Bargallo, Sjoerd Nicolaas Wadman
-
Publication number: 20150031602Abstract: Provided are compounds, the use of the said compounds in treatment, for example treatment of microbial infections, particularly by Gram negative bacteria. The compounds are polymyxin-based and are represented by the formula (I): and pharmaceutically acceptable salts thereof, where X is —NHC(O)—, —C(O)—, —OC(O)—, —CH2— or —SO2—; R5 represents C0-12 alkyl(C4-6 heterocyclyl), or C2-12 alkyl or C0-12 alkyl(C3-8 cycloalkyl). and the alkyl or cycloalkyl bears one, two or three hydroxyl groups, or a —NR6R7 group, or one —NR6R7 group and one or two hydroxyl groups; and R1 to R4 and R6 to R8 are as defined in the description.Type: ApplicationFiled: November 16, 2012Publication date: January 29, 2015Applicants: CANTAB ANTI-INFECTIVES LIMITED, NOVACTA BIOSYSTEMS LIMITEDInventors: Mona Saadi, Esther Duperchy, Pamela Brown, Michael John Dawson, Sjoerd Nicolaas Wadman
-
Patent number: 8575094Abstract: A method for the treatment or prophylaxis of a microbial infection of the lower intestine or colon in a subject is described, wherein the method comprises administration to the subject of a type-B lantibiotic, wherein the type-B lantibiotic may include compounds selected from the group consisting of mersacidin, actagardine, plantaricin, planosporicin, ruminococcin, antibiotic 10789, michiganin and haloduracin, and derivatives and variants thereof.Type: GrantFiled: January 21, 2009Date of Patent: November 5, 2013Assignee: Novacta Biosystems LimitedInventors: Sjoerd Nicolaas Wadman, Michael John Dawson, Jesus Cortes Bargallo
-
Patent number: 8465947Abstract: Characterization of the biosynthetic gene cluster for the lantibiotic antibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine, a novel actagardine variant, herein referred to as actagardine B, and variants of both of these produced according to this invention, utilizing genes from the characterized biosynthetic gene clusters, is described.Type: GrantFiled: June 10, 2011Date of Patent: June 18, 2013Assignee: Novacta Biosystems LimitedInventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson
-
Publication number: 20120302728Abstract: Described are lantibiotic-based compounds, pharmaceutical compositions comprising the same and use of the compounds and said compositions, for the treatment of microbial infection, for example Clostridium difficile or Micrococcus luteus infection. The lantibiotic-based compounds have antimicrobial activity and in comparison to one or more of actagardine, actagardine B, deoxyactagardine B and deoxyactagardine have retained activity or improved activity.Type: ApplicationFiled: February 1, 2011Publication date: November 29, 2012Inventors: Michael John Dawson, Antony Nicholas Appleyard, Jesus Cortes Bargallo, Sjoerd Nicolaas Wadman
-
Patent number: 8183202Abstract: A method for the treatment or prophylaxis of a microbial infection of the lower intestine or colon in a subject is described, wherein the method comprises administration to the subject of a type-B lantibiotic, wherein the type-B lantibiotic may include compounds selected from the group consisting of mersacidin, actagardine, plantaricin, planosporicin, ruminococcin, antibiotic 10789, michiganin and haloduracin, and derivatives and variants thereof.Type: GrantFiled: January 21, 2009Date of Patent: May 22, 2012Assignee: Novacta Biosystems LimitedInventors: Sjoerd Nicolaas Wadman, Michael John Dawson, Jesus Cortes Bargallo
-
Publication number: 20110306091Abstract: This invention relates to characterisation of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine, a novel actagardine variant, herein referred to as actagardine B, and variants of both of these produced according to this invention, utilizing genes from the characterised biosynthetic gene clusters.Type: ApplicationFiled: June 10, 2011Publication date: December 15, 2011Applicant: Novacta Biosystems LimitedInventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson
-
Patent number: 7989416Abstract: Characterization of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine are described.Type: GrantFiled: January 17, 2007Date of Patent: August 2, 2011Assignee: Novacta Biosystems LimitedInventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson
-
Publication number: 20100048459Abstract: This invention relates to characterisation of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine, a novel actagardine variant, herein referred to as actagardine B, and variants of both of these produced according to this invention, utilizing genes from the characterised biosynthetic gene clusters.Type: ApplicationFiled: January 17, 2007Publication date: February 25, 2010Inventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson
-
Patent number: 7592308Abstract: The present invention relates to methods and products for improved production of the lantibiotic mersacidin. There is provided a method of producing a mersacidin variant which comprises introducing into a cell which is a ?MrsA host cell an expression vector encoding said variant, and recovering said variant from the cell culture. Preferred variants include the novel variants of Table 1, e.g. mersacidin F3W, said mersacidin F3W optionally having a further one or more variations, e.g. mersacidin F3W G8A. Also provided is a Bacillus cell which is a SigH deficient strain of Bacillus sp. HIL Y-85,54728 (NCIMB Accession Number NCIMB 41211); this cell may also be used in the production of mersacidin and its variants. Further aspects of the invention include a DNA cassette which comprises a nucleotide sequence encoding the mersacidin mrsA propeptide, and a method to transform a Bacillus HIL host cell with plasmid, which method includes the step of electroporation.Type: GrantFiled: September 25, 2006Date of Patent: September 22, 2009Assignee: Novacta Biosystems LimitedInventors: Michael John Dawson, Jesus Cortes Bargallo, Antony Nicholas Appleyard, Brian Arthur Michael Rudd, Steven Boakes, Gabriele Bierbaum, Anja Hoffmann, Stephanie Schmitz
-
Publication number: 20090203583Abstract: The present invention provides methods for the treatment or prophylaxis of a microbial infection of the lower intestine or colon in a subject, the method comprising administering to the subject a type-B lantibiotic. In particular, the invention provides methods for the treatment or prophylaxis of a Clostridium difficile infection. The type-B lantibiotics may include compounds selected from the group consisting of mersacidin, actagardine, plantaricin, planosporicin, ruminococcin, antibiotic 10789, michiganin and haloduracin, and derivatives and variants thereof.Type: ApplicationFiled: January 21, 2009Publication date: August 13, 2009Applicant: Novacta Biosystems LimitedInventors: Sjoerd Nicolaas Wadman, Michael John Dawson, Jesus Cortes Bargallo
-
Patent number: 6340587Abstract: The present invention relates to a process for the preparation of enantiomerically enriched N-derivatized (1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-ones by use of an enzyme.Type: GrantFiled: February 14, 2000Date of Patent: January 22, 2002Assignee: SmithKline Beecham CorporationInventors: Michael John Dawson, Mahmoud Mahmoudian, Christopher John Wallis
-
Patent number: 6156544Abstract: A method for the preparation of N-acetyl-D-neuraminic acid (NANA) N-acetyl-D-glucosamine (NAG) is described.Type: GrantFiled: July 2, 1998Date of Patent: December 5, 2000Assignee: Glaxo Group LimitedInventors: Michael John Dawson, David Noble, Mahmoud Mahmoudian
-
Patent number: RE45003Abstract: Characterization of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine are described.Type: GrantFiled: December 4, 2012Date of Patent: July 8, 2014Assignee: Novacta Biosystems LimitedInventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson